Home / Themes / GLP-1 Short '24: Obesity-Linked MedTech
GLP-1 Short '24: Obesity-Linked MedTech (view performance)
Last updated
Theme thesis · 4/5 sections · Tickers 5 with notes · 9 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsAs of Spring 2025, the thesis for the GLP-1 '24: Medical Devices & Monitoring subtheme is bearish. The advent of GLP-1 drugs has significantly reduced the need
Thesis
As of Spring 2025, the thesis for the GLP-1 '24: Medical Devices & Monitoring subtheme is bearish. The advent of GLP-1 drugs has significantly reduced the need for medical devices and monitoring tools that are traditionally used for managing obesity-related conditions. This shift is expected to negatively impact companies that manufacture or sell devices for diabetes management, sleep apnea, and bariatric surgery.
Bull case
GLP-1 drugs have proven effective in reducing obesity rates, decreasing the need for devices like CPAP machines and insulin pumps.
Companies like ResMed (RMD) and Inspire Medical Systems (INSP) are experiencing declining sales due to reduced demand for sleep apnea devices.
The shift towards pharmaceutical solutions over surgical interventions is diminishing the market for bariatric surgery-related equipment from companies like Teleflex (TFX).
Bear case
Despite the reduction in obesity, the aging population may still drive demand for certain medical devices, providing a cushion for companies like DaVita (DVA) and Fresenius Medical Care (FMS).
Innovations in medical technology and monitoring could present new opportunities for growth in niche markets, potentially offsetting declines.
Some patients may experience side effects from GLP-1 drugs, leading to a continued need for monitoring devices from companies like Tandem Diabetes Care (TNDM) and Insulet (PODD).
Overview
Hiring Trend Watchpoints
High-performing operators in this theme are demonstrating adaptive hiring strategies. For companies like ResMed (RMD), watch for increased hiring in sales and marketing for PAP therapy, particularly roles focused on patient engagement and education for newly diagnosed sleep apnea patients, including those on GLP-1s. R&D roles for integrated sleep health solutions would confirm a bullish adaptation. For Insulet (PODD) and Tandem Diabetes Care (TNDM), monitor hiring for Type 2 diabetes market expansion (sales, clinical educators), and R&D for advanced automated insulin delivery (AID) algorithms, sensor integrations (e.g., FreeStyle Libre 3 Plus), and new form factors (Mobi Tubeless). Growth in T2D-focused commercial teams and R&D for next-gen pumps/CGM integration would confirm theme execution (i.e., these companies are adapting to mitigate GLP-1 impact). For Fresenius Medical Care (FMS), look for hiring related to the 5008X CAREsystem rollout (nurses, technicians, operational support for clinic conversions) and Value-Based Care segment expansion. For Teleflex (TFX), hiring in Vascular, Interventional, and Surgical segments, particularly R&D roles focused on innovation in these core areas post-divestiture, would signal successful strategic transformation. AdaptHealth (AHCO) is hiring approximately 1,200 employees across ~30 locations to support its capitated contract ramp-up and expanding AI/automation specialists for operational efficiency, despite a recent workforce reduction in Q2 2026. Confirmation of successful onboarding for these capitated contracts and growth in AI/automation roles would be bullish for AHCO. Conversely, significant reductions in sales/marketing for traditional obesity-related devices or hiring freezes in core growth areas would warn of theme deterioration (i.e., GLP-1s negatively impacting demand).
Forum Watchlist
- Reddit — r/diabetesHigh
Patient experiences with GLP-1s and diabetes device usage, impact on insulin needs, new product discussions.
- Reddit — r/CPAPHigh
Discussions on GLP-1 impact on sleep apnea severity, CPAP adherence, and new treatment alternatives.
- Community Forum — Beyond Type 1Medium
Discussions among Type 1 and Type 2 diabetes patients on GLP-1 effects, pump/CGM preferences, and new technology adoption.
- Community Forum — Diabetes DailyMedium
Patient perspectives on diabetes management, GLP-1 experiences, and device effectiveness.
- Community Forum — Apnea BoardMedium
Technical discussions and user experiences with sleep apnea devices, treatment efficacy, and alternative therapies.
- Investor Forum — The MedTech Conference Investor ForumHigh
Investor sentiment, strategic priorities of medtech companies, and discussions on market disruptions like GLP-1s.
- Investor Forum — Octane's Medical Innovation ForumMedium
Showcase of medtech startups and innovators, capital flow, and emerging trends in medical devices.
- Professional Forum — DiabetesPro Member Forum (ADA)High
Clinical discussions among diabetes and obesity professionals on emerging therapies, best practices, and real-world case studies.
Industry Publications
- MassDevice (massdevice.com) — Comprehensive coverage of medical device news, FDA approvals, and industry trends.
- Medical Device and Diagnostic Industry (MD+DI) (mddionline.com) — In-depth articles on medical device development, regulation, and market analysis.
- Fierce Medtech (fiercemedtech.com) — Daily news and analysis on the medical technology sector, including M&A and clinical trials.
- Sleep Review (sleepreviewmag.com) — Dedicated to sleep medicine, covering devices, therapies, and market dynamics for sleep apnea.
- Nephrology News & Issues (nephrologynews.com) — Focuses on kidney care, dialysis, and related medical devices and policy changes.
- Diabetes Technology Society (diabetestechnology.org) — Covers advancements in diabetes devices, continuous glucose monitoring, and insulin delivery systems.
- Endocrine Today (healio.com/endocrine-today) — Clinical news and research for endocrinologists, including diabetes and obesity treatments.
- The Journal of Healthcare Contracting (jhconline.com) — Covers news and trends in healthcare contracting, relevant for HME providers and device manufacturers.
Second Order Trends
Several second-order trends are emerging within the GLP-1 Short '24: Medical Devices & Monitoring theme, indicating a more nuanced impact than a simple decline in device demand. Firstly, ResMed (RMD) is actively reframing GLP-1s as a potential 'tailwind' for sleep apnea diagnosis and treatment. Recent data suggests that weight loss from GLP-1s can increase patient engagement with healthcare, leading to higher diagnosis rates for sleep-disordered breathing and improved adherence to PAP therapy. This counters the initial bearish thesis for sleep apnea devices. Secondly, strategic divestitures and portfolio focus are becoming prominent. Teleflex (TFX) completed the divestiture of its OEM business for $1.5 billion in August 2026, aiming to sharpen its focus on higher-growth Vascular, Interventional, and Surgical segments. Similarly, AdaptHealth (AHCO) entered an agreement to sell its Diabetes Health business for $235 million in cash, concentrating its portfolio on Sleep Health, Respiratory Health, and Wellness-at-Home. These moves reflect companies adapting to market shifts, including the evolving GLP-1 landscape. Thirdly, diabetes device companies like Insulet (PODD) and Tandem Diabetes Care (TNDM) are aggressively expanding their addressable market. Tandem received CE mark for expanded indications of its AID systems for Type 1 diabetes during pregnancy and adults with Type 2 diabetes. Insulet rolled out enhanced Omnipod 5 compatibility with Abbott's FreeStyle Libre 3 Plus sensor, broadening CGM options and simplifying automated insulin delivery. Both companies are also focusing on pharmacy channel expansion and 'PayGo' models to improve accessibility and lower upfront costs, potentially accelerating adoption in the large Type 2 diabetes market. Fourthly, the shift towards value-based care and operational efficiency is accelerating, particularly for Home Medical Equipment (HME) providers. AdaptHealth (AHCO) is deepening its commitment to capitated agreements with large IDNs and payers, aiming for predictable recurring revenue and higher margins, supported by investments in AI and automation. Lastly, Fresenius Medical Care (FMS) is undertaking a significant rollout of its 5008X CAREsystem in the U.S., introducing high-volume hemodiafiltration (HVHDF) to improve patient outcomes and operational efficiencies in dialysis. FMS views GLP-1s as a potential 'mortality benefit' that could extend patient life, thereby increasing the duration of dialysis treatment. This highlights that for certain life-sustaining devices, GLP-1s may present an indirect positive rather than a negative impact.
Search Keywords Brand Product
- Ozempic
- Wegovy
- Mounjaro
- Zepbound
- Rybelsus
- CagriSema
- CPAP machines
- insulin pumps
- continuous glucose monitors
- Omnipod 5
- t:slim X2
- Tandem Mobi
- Control-IQ+
- FreeStyle Libre 3 Plus
- 5008X CAREsystem
- high-volume hemodiafiltration
Search Keywords Policy Regulatory
- CMS competitive bidding program
- ESRD PPS rule
- ACA tax subsidies
- C-peptide testing
- FDA GLP-1 approval
- Medicare GLP-1 coverage
Search Keywords Event Phrases
- ADA Scientific Sessions
- EASD Annual Meeting
- MedTech Conference
- LSI Emerging Medtech Summit
- SLEEP conference
Google Trend Product Category Intent
• weight loss drugs
• diabetes medication
• sleep apnea treatment
• insulin pump cost
• CGM price
• dialysis machine
Google Trend Consumer Intent
• lose weight fast
• diabetes management
• sleep apnea symptoms
• kidney dialysis
• how to get GLP-1
Google Trend Macro Policy Terms
• GLP-1 insurance coverage
• Medicare diabetes coverage
• FDA weight loss drug approval
Top datasets to track
1. GLP-1 Prescription Rates Type: Proprietary/Vendor · Provider: IQVIA Cadence: Monthly Why it matters: Tracks the adoption rate and market impact of GLP-1 drugs, directly influencing demand for related medical devices. Suggested query: IQVIA GLP-1 prescription data Confidence: High
2. CMS Competitive Bidding Program Updates Type: Government/Regulatory · Provider: CMS Cadence: As announced Why it matters: The final rule and award structure can materially reshape industry reimbursement and market concentration for HME providers like AdaptHealth. Suggested query: CMS competitive bidding program 2026 updates Confidence: High
3. Diabetes Device Sales & New Patient Starts (Type 2) Type: Company/Industry · Provider: Company reports (PODD, TNDM), industry associations Cadence: Quarterly Why it matters: Monitors the underlying demand for insulin pumps and CGMs, especially penetration into the Type 2 diabetes market, which can offset GLP-1 impacts. Suggested query: Insulet Type 2 new customer starts, Tandem Diabetes Care pump shipments Confidence: High
4. Sleep Apnea Device Sales & Patient Census Type: Company/Industry · Provider: Company reports (RMD, AHCO), industry associations Cadence: Quarterly Why it matters: Tracks demand for CPAP/APAP devices and patient populations, crucial for assessing the evolving GLP-1 impact on sleep-disordered breathing. Suggested query: ResMed sleep apnea device sales, AdaptHealth Sleep Health census Confidence: High
5. Dialysis Patient Census / Treatment Volumes (U.S.) Type: Company/Industry · Provider: Company reports (FMS, DVA) Cadence: Quarterly Why it matters: Indicates stability or changes in the end-stage renal disease market, which is a core business for FMS and DVA, and may be indirectly affected by GLP-1s extending patient longevity. Suggested query: Fresenius Medical Care U.S. same-market treatment growth Confidence: High
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| GLP-1 prescription rates | Monthly | Tracks the adoption rate and market impact | Google_Sheets |
Upcoming Catalysts
| Catalyst | Estimated Timing | Estimated Date Start | Estimated Date End | Why It Matters | Ticker Or Theme Specific | Source Types | Contributing Tickers | Mention Count | Bridge Mention Count | Base Score | Theme Base Score | Source Weight | Specificity Weight | Macro Bridge | Macro Bridge Multiplier | Theme Importance Score | Theme Score | Manual Override | Date Aggregated | Catalyst Source | Catalyst ID | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA clearance for Mobi Tubeless, enabling its commercial launch. | second half of the year | 2026-07-01 | 2026-12-31 | Regulatory approval is necessary to launch this significant new product, which is Tandem's first patch pump and the world's first with extended wear technology, potentially impacting market share and revenue. | Theme | earnings_transcript | TNDM | 4 | 4 | 0.0001 | 0.6004 | 1.25 | 0.92 | Regulatory/Policy | 1.35 | 93.2101 | 0.0106 | False | 2026-03-16 | Theme aggregation | |||
| Commercial launch of Mobi Tubeless, a novel infusion site option for the Mobi pump that transforms it into a tubeless patch device. | second half of the year | 2026-07-01 | 2026-12-31 | Introduces a new form factor and technology, potentially expanding Tandem's addressable market and competitive position against patch pump competitors, though not included in 2026 revenue guidance. | Theme | earnings_transcript | TNDM | 4 | 4 | 0.0001 | 0.6004 | 1.25 | 0.92 | Regulatory/Policy | 1.35 | 93.2101 | 0.0106 | False | 2026-03-16 | Theme aggregation | |||
| Initiation of a pivotal trial for Tandem's fully closed-loop automated insulin delivery algorithm. | later this year | 2026-07-01 | 2026-12-31 | A crucial step towards developing a next-generation AID system, aiming for FDA filing in 2027, which is vital for maintaining Tandem's leadership in AID innovation. | Theme | earnings_transcript | TNDM | 4 | 4 | 0.0001 | 0.6004 | 1.25 | 0.92 | Regulatory/Policy | 1.35 | 93.2101 | 0.0106 | False | 2026-03-16 | Theme aggregation | |||
| Effectiveness of diabetes segment recovery initiatives (expanded diabetes sales force and pharmacy/channel investments) to drive a rebound in CGM new starts and continued pump growth. | later in 2026 | 2026-07-01 | 2026-12-31 | Diabetes performance is a key swing factor for organic growth and valuation; a tangible rebound in new starts would be bullish (restores a previously weak segment and supports guidance), while persistent softness would reinforce downside risk from secular pressures (including GLP‑1 adoption) and hurt revenue and margin outlooks. | Theme | earnings_transcript | AHCO | 4 | 4 | 0.0001 | 0.6004 | 1.25 | 0.92 | Regulatory/Policy | 1.35 | 93.2068 | 0.01 | False | 2026-03-16 | Theme aggregation | |||
| Deployment of approximately $1.8 billion in net proceeds from divestitures, including a $1.0 billion share repurchase and $800 million debt repayment. | following the closings of the transactions | 2026-03-01 | 2026-12-31 | These actions are expected to significantly reduce share count and interest expense, leading to a 'meaningfully higher adjusted EPS in 2027 and beyond.' | Theme | earnings_transcript | TFX | 2 | 2 | 0.0002 | 0.2012 | 1.25 | 0.92 | Regulatory/Policy | 1.35 | 31.2438 | 0.0273 | False | 2026-03-16 | Theme aggregation | |||
| FDA clearance for Control-IQ+ technology with a pregnancy indication. | recently submitted a 510(k) | 2026-03-01 | 2026-12-31 | Expands the indicated use of Control-IQ+, potentially increasing its addressable market and sales by serving a new patient population. | Theme | earnings_transcript | TNDM | 2 | 2 | 0.0001 | 0.2004 | 1.25 | 0.92 | Regulatory/Policy | 1.35 | 31.1101 | 0.0085 | False | 2026-03-16 | Theme aggregation | |||
| Clarity on the imposition of additional tariffs (10% or 15%) or potential relief from existing tariffs following a recent Supreme Court decision. | now there is certainly some significant uncertainty | 2026-02-27 | 2026-12-31 | Tariffs directly impact gross margin. A favorable resolution could provide upside to current guidance, while additional tariffs could further pressure profitability. | Theme | earnings_transcript | TFX | 1 | 1 | 0.0002 | 0.0012 | 1.25 | 0.92 | Regulatory/Policy, Court/Legal | 1.755 | 0.2519 | 0.0399 | False | 2026-03-16 | Theme aggregation | |||
| Completion of the sale of Teleflex's Acute Care, Interventional Urology, and OEM businesses to two separate buyers. | continue to expect the sales to close in 2026 | 2026-03-01 | 2026-12-31 | This transaction will yield $1.8 billion in net after-tax proceeds, which will be used for significant capital deployment, and will enable the recognition of TS and MS fees to offset stranded costs. | Theme | earnings_transcript | TFX | 1 | 1 | 0.0002 | 0.0012 | 1.25 | 0.92 | Regulatory/Policy, Economic | 1.688 | 0.2422 | 0.0375 | False | 2026-03-16 | Theme aggregation | |||
| Appointment of a new permanent Chief Executive Officer for Teleflex Incorporated. | actively conducting a CEO search | 2026-03-01 | 2026-09-30 | The new CEO will define the long-term strategic direction and operational focus for the 'RemainCo,' impacting investor sentiment and future growth initiatives. | Ticker | earnings_transcript | TFX | 1 | 1 | 0.0001 | 0.001 | 1.25 | 0.92 | 1.0 | 0.1186 | 0.0142 | False | 2026-03-16 | Theme aggregation | ||||
| Full mitigation of $90 million in stranded costs through transition service and manufacturing service agreements, and the completion of a restructuring plan targeting $50 million in annual pre-tax savings. | TS/MS agreements during a transitionary period of time after divestiture close (2026). Restructuring plan substantially completed by mid-2028. | 2026-03-01 | 2028-06-30 | Successful mitigation of these costs is critical for improving adjusted operating margin from the guided 19% in 2026 to an underlying steady-state of approximately 23% and driving significant EPS growth in 2027 and beyond. | Ticker | earnings_transcript | TFX | 1 | 1 | 0.0001 | 0.001 | 1.25 | 0.85 | 1.0 | 0.1096 | 0.0131 | False | 2026-03-16 | Theme aggregation | ||||
| CMS competitive bidding program final rule and subsequent contract awards/implementation for the next round of bidding. | upcoming round of competitive bidding (timing uncertain in 2026) | 2026-01-01 | 2026-12-31 | The final rule and award structure can materially reshape industry reimbursement and market concentration; a rule that consolidates awards to large, efficient providers would be bullish for AdaptHealth (share gains), while aggressive rate cuts or broader exclusions could compress margins across Sleep/Respiratory (bearish). | Theme | earnings_transcript | AHCO | 1 | 1 | 0.0 | 0.0004 | 1.25 | 0.92 | 1.0 | 0.0421 | 0.0049 | False | 2026-03-16 | Theme aggregation | ||||
| Full implementation and operationalization of new sales systems in the United States. | in 2026 | 2026-01-01 | 2026-12-31 | Expected to provide significant efficiencies and benefits to the sales team, potentially impacting US sales growth and productivity. | Ticker | earnings_transcript | TNDM | 1 | 1 | 0.0 | 0.0003 | 1.25 | 0.92 | 1.0 | 0.0368 | 0.0044 | False | 2026-03-16 | Theme aggregation | ||||
| Quarterly revenue contribution from the capitated contract is expected to add incremental percentage points each quarter, culminating in low-double-digit year‑over‑year growth contribution by Q4 2026. | ramping throughout 2026, peaking at low double‑digits by Q4 2026 | 2026-01-01 | 2026-12-31 | The timing and magnitude of this revenue ramp drive full‑year revenue growth and margin expansion; faster-than-expected ramp is bullish (greater operating leverage), while a slower or smaller ramp is bearish (prolonged margin pressure and higher net leverage). | Ticker | earnings_transcript | AHCO | 1 | 1 | 0.0 | 0.0003 | 1.25 | 0.92 | 1.0 | 0.0348 | 0.0042 | False | 2026-03-16 | Theme aggregation | ||||
| Rollout of successful AI pilots (order intake AI and conversational AI for PAP self‑scheduling) to additional regions. | in 2026 | 2026-01-01 | 2026-12-31 | Broader deployment could reduce processing times and labor costs and provide margin improvement over time; material upside if deployments accelerate operating leverage beyond current guidance, but rollout delays or underperformance would limit anticipated cost savings. | Ticker | earnings_transcript | AHCO | 1 | 1 | 0.0 | 0.0003 | 1.25 | 0.92 | 1.0 | 0.0348 | 0.0042 | False | 2026-03-16 | Theme aggregation | ||||
| Pursuit and potential closing of tuck‑in acquisitions (equipment/operations) to support West Coast/Hawaii onboarding and broader capitated operations, and associated revolver usage/paydown. | through 2026 | 2026-02-24 | 2026-12-31 | Small acquisitions can smooth transitions and add local capacity (bullish if accretive and enables faster ramp); conversely, additional draws or mis‑timed purchases could elevate leverage or integration risk and pressure near‑term liquidity and margins. | Ticker | earnings_transcript | AHCO | 1 | 1 | 0.0 | 0.0003 | 1.25 | 0.92 | 1.0 | 0.0348 | 0.0042 | False | 2026-03-16 | Theme aggregation | ||||
| Full implementation and scaling of the pay-as-you-go (PayGo) reimbursement model in the pharmacy channel for both t:slim X2 and Mobi platforms. | beginning late in the first quarter and scaling over the course of 2 to 3 years | 2026-03-01 | 2029-02-20 | This transformational business model change is expected to drive market expansion by reducing upfront costs for customers and improve long-term profitability through higher recurring supply revenue, despite a near-term sales headwind of $70M-$80M in 2026. | Ticker | earnings_transcript | TNDM | 1 | 1 | 0.0 | 0.0003 | 1.25 | 0.85 | 1.0 | 0.034 | 0.0041 | False | 2026-03-16 | Theme aggregation | ||||
| Quarterly revenue contribution from AHCO's capitated contract is expected to add incremental percentage points each quarter, culminating in low-double-digit year-over-year growth contribution by Q4 2026. | ramping throughout 2026, peaking at low double-digits by Q4 2026 | 2026-01-01 | 2026-12-31 | The timing and magnitude of this revenue ramp drive full-year revenue growth and margin expansion; faster-than-expected ramp is bullish, while a slower or smaller ramp is bearish. | Ticker | earnings_transcript | AHCO | 1 | 0.0 | 1.25 | 0.92 | 1.0 | 0.0037 | False | 2026-02-28 | Theme composer | |||||||
| AHCO plans the rollout of successful AI pilots (order intake AI and conversational AI for PAP self-scheduling) to additional regions. | in 2026 | 2026-01-01 | 2026-12-31 | Broader deployment could reduce processing times and labor costs and provide margin improvement over time; material upside if deployments accelerate operating leverage beyond current guidance. | Ticker | earnings_transcript | AHCO | 1 | 0.0 | 1.25 | 0.92 | 1.0 | 0.0037 | False | 2026-02-28 | Theme composer | |||||||
| The CMS competitive bidding program's final rule and subsequent contract awards/implementation for the next round of bidding are expected. | upcoming round of competitive bidding (timing uncertain in 2026) | 2026-01-01 | 2026-12-31 | The final rule and award structure can materially reshape industry reimbursement and market concentration; a rule that consolidates awards to large, efficient providers would be bullish for AdaptHealth, while aggressive rate cuts or broader exclusions could compress margins across Sleep/Respiratory. | Theme | earnings_transcript | AHCO | 1 | 0.0 | 1.25 | 0.92 | 1.0 | 0.0045 | False | 2026-02-28 | Theme composer | |||||||
| AHCO is pursuing and potentially closing tuck-in acquisitions (equipment/operations) to support West Coast/Hawaii onboarding and broader capitated operations, with associated revolver usage/paydown. | through 2026 | 2026-02-24 | 2026-12-31 | Small acquisitions can smooth transitions and add local capacity; conversely, additional draws or mis-timed purchases could elevate leverage or integration risk and pressure near-term liquidity and margins. | Ticker | earnings_transcript | AHCO | 1 | 0.0 | 1.25 | 0.92 | 1.0 | 0.0037 | False | 2026-02-28 | Theme composer | |||||||
| Quarterly revenue contribution from the capitated contract is expected to add incremental percentage points each quarter, culminating in low-double-digit year‑over‑year growth contribution by Q4 2026. | ramping throughout 2026, peaking at low double‑digits by Q4 2026 | 2026-01-01 | 2026-12-31 | The timing and magnitude of this revenue ramp drive full‑year revenue growth and margin expansion; faster-than-expected ramp is bullish (greater operating leverage), while a slower or smaller ramp is bearish (prolonged margin pressure and higher net leverage). | Ticker | AHCO (ticker) | AHCO_8190a9c8 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Rollout of successful AI pilots (order intake AI and conversational AI for PAP self‑scheduling) to additional regions. | in 2026 | 2026-01-01 | 2026-12-31 | Broader deployment could reduce processing times and labor costs and provide margin improvement over time; material upside if deployments accelerate operating leverage beyond current guidance, but rollout delays or underperformance would limit anticipated cost savings. | Ticker | AHCO (ticker) | AHCO_5c48eab9 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Effectiveness of diabetes segment recovery initiatives (expanded diabetes sales force and pharmacy/channel investments) to drive a rebound in CGM new starts and continued pump growth. | later in 2026 | 2026-07-01 | 2026-12-31 | Diabetes performance is a key swing factor for organic growth and valuation; a tangible rebound in new starts would be bullish (restores a previously weak segment and supports guidance), while persistent softness would reinforce downside risk from secular pressures (including GLP‑1 adoption) and hurt revenue and margin outlooks. | Ticker | AHCO (ticker) | AHCO_00fc6f4a | 2026-02-24 | earnings_transcript | ||||||||||||||
| Pursuit and potential closing of tuck‑in acquisitions (equipment/operations) to support West Coast/Hawaii onboarding and broader capitated operations, and associated revolver usage/paydown. | through 2026 | 2026-02-24 | 2026-12-31 | Small acquisitions can smooth transitions and add local capacity (bullish if accretive and enables faster ramp); conversely, additional draws or mis‑timed purchases could elevate leverage or integration risk and pressure near‑term liquidity and margins. | Ticker | AHCO (ticker) | AHCO_e7c66252 | 2026-02-24 | earnings_transcript | ||||||||||||||
| CMS competitive bidding program final rule and subsequent contract awards/implementation for the next round of bidding. | upcoming round of competitive bidding (timing uncertain in 2026) | 2026-01-01 | 2026-12-31 | The final rule and award structure can materially reshape industry reimbursement and market concentration; a rule that consolidates awards to large, efficient providers would be bullish for AdaptHealth (share gains), while aggressive rate cuts or broader exclusions could compress margins across Sleep/Respiratory (bearish). | Theme | AHCO (ticker) | AHCO_2dab6ea0 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Large-scale rollout of the 5008X CAREsystem and high-volume hemodiafiltration (HV-HDF) therapy in U.S. clinics, targeting 20% of the installed base in 2026. | in 2026, target of replacing around 20% of the installed base in our own clinics this year | 2026-01-01 | 2026-12-31 | This strategic initiative is expected to improve patient outcomes, increase operational efficiencies, and strengthen FMS's competitive position, but will incur OpEx headwinds in 2026. Successful execution is crucial for future growth and market share. | Ticker | FMS (ticker) | FMS_a8b53d93 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Phasing out of temporary TDAPA (Transitional Drug Add-on Payment Adjustment) benefits for phosphate binders and antimicrobial catheter solutions. | start to phase out in 2026, stronger first half of 2026 before TDAPA benefits begin to phase out in the second half of 2026 | 2026-07-01 | 2026-12-31 | These benefits provided a significant positive contribution to earnings in 2025. Their phase-out will create a regulatory headwind of EUR 150M-EUR 200M in 2026, impacting profitability, with uncertainty around the exact erosion of branded pricing and future bundle payments. | Ticker | FMS (ticker) | FMS_b10690dc | 2026-02-24 | earnings_transcript | ||||||||||||||
| Continued negative impact from volume-based procurement and other regulatory policies in China on the Care Enablement segment. | expected to impact 2026, China remains challenging, and we are assuming moderately negative impact as we address regulatory policy changes and review our portfolio and strategy accordingly | 2026-01-01 | 2026-12-31 | These policies weighed on revenue and earnings in Q4 2025 and are expected to continue to negatively impact the segment's performance in 2026, with the magnitude dependent on FMS's strategic adjustments. | Ticker | FMS (ticker) | FMS_ed8c2ef3 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Expiry of extended tax subsidies for Affordable Care Act (ACA) contracts. | 2026 outlook, regulatory headwinds from the expiry of the extended tax subsidies for ACA contracts | 2026-01-01 | 2026-12-31 | This regulatory headwind is expected to negatively impact earnings development, contributing to the EUR 150M-EUR 200M regulatory impact in 2026, with the full extent of the financial impact still being assessed. | Ticker | FMS (ticker) | FMS_9d8ae73c | 2026-02-24 | earnings_transcript | ||||||||||||||
| Recovery of U.S. same-market treatment growth (SMTG) from flat in 2026 towards the historical 2%+ baseline. | returning to 2%-plus as mortality normalizes and patient outflows improve, gradually improve over time to get back to that 2% plus | 2026-01-01 | 2028-12-31 | SMTG is a critical driver of revenue and operating leverage. A sustained recovery would signal normalization of patient mortality and successful strategic initiatives, positively impacting long-term growth and valuation. | Ticker | FMS (ticker) | FMS_5e50f090 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Realization of an additional EUR 400 million in sustainable savings from the accelerated FME25+ transformation program by the end of 2027, with EUR 250 million incremental savings expected in 2026. | for the years '26 and 2027 for a total of EUR 1.2 billion of sustainable savings by the end of 2027, incremental FME25+ savings of EUR 250 million with related onetime cost of EUR 350 million in 2026 | 2026-01-01 | 2027-12-31 | This program is a key driver of profitability improvements, aiming for EUR 1.2 billion in total sustainable savings by 2027. Successful execution will significantly boost margins and earnings, offsetting inflationary pressures. | Ticker | FMS (ticker) | FMS_23d3f509 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Commercial launch of Omnipod 5 in Spain, a new international market. | Spain, our newest market, is expected to launch Omnipod 5 later this year. | 2026-07-01 | 2026-12-31 | Entry into new geographies is a key component of Insulet's international growth strategy, driving volume and market share gains, which directly impacts revenue and investor sentiment. | Ticker | PODD (ticker) | PODD_4c284f22 | 2026-02-18 | earnings_transcript | ||||||||||||||
| Full implementation and operationalization of new sales systems in the United States. | in 2026 | 2026-01-01 | 2026-12-31 | Expected to provide significant efficiencies and benefits to the sales team, potentially impacting US sales growth and productivity. | Ticker | TNDM (ticker) | TNDM_f826e8b2 | 2026-02-20 | earnings_transcript | ||||||||||||||
| FDA clearance for Mobi Tubeless, enabling its commercial launch. | second half of the year | 2026-07-01 | 2026-12-31 | Regulatory approval is necessary to launch this significant new product, which is Tandem's first patch pump and the world's first with extended wear technology, potentially impacting market share and revenue. | Ticker | TNDM (ticker) | TNDM_82e30c2b | 2026-02-20 | earnings_transcript | ||||||||||||||
| Commercial launch of Mobi Tubeless, a novel infusion site option for the Mobi pump that transforms it into a tubeless patch device. | second half of the year | 2026-07-01 | 2026-12-31 | Introduces a new form factor and technology, potentially expanding Tandem's addressable market and competitive position against patch pump competitors, though not included in 2026 revenue guidance. | Ticker | TNDM (ticker) | TNDM_a7005c10 | 2026-02-20 | earnings_transcript | ||||||||||||||
| Initiation of a pivotal trial for Tandem's fully closed-loop automated insulin delivery algorithm. | later this year | 2026-07-01 | 2026-12-31 | A crucial step towards developing a next-generation AID system, aiming for FDA filing in 2027, which is vital for maintaining Tandem's leadership in AID innovation. | Ticker | TNDM (ticker) | TNDM_8eea9c45 | 2026-02-20 | earnings_transcript | ||||||||||||||
| Full implementation and scaling of the pay-as-you-go (PayGo) reimbursement model in the pharmacy channel for both t:slim X2 and Mobi platforms. | beginning late in the first quarter and scaling over the course of 2 to 3 years | 2026-03-01 | 2029-02-20 | This transformational business model change is expected to drive market expansion by reducing upfront costs for customers and improve long-term profitability through higher recurring supply revenue, despite a near-term sales headwind of $70M-$80M in 2026. | Ticker | TNDM (ticker) | TNDM_66b9a22c | 2026-02-20 | earnings_transcript | ||||||||||||||
| Transition to direct commercial operations in additional key European markets, following the playbook from initial transitions. | in the fourth quarter | 2026-10-01 | 2026-12-31 | Expected to improve price and margins (ASP premiums at least 30% higher) and deepen relationships, but also involves an anticipated $15 million headwind from distributor destocking and inventory buybacks for 2026. | Ticker | earnings_transcript | TNDM | 1 | 1 | 0.0 | 0.0003 | 1.25 | 1.0 | 1.0 | 0.04 | 0.0048 | False | 2026-03-16 | Theme aggregation | ||||
| Start of pivotal trial for MiniMed's next-generation extended wear sensor in the U.S. | October | 2026-10-01 | 2026-10-31 | This program demonstrates continued innovation beyond current products, aiming to improve user experience, strengthen competitive position, and be accretive to margins through longer wear duration. | Ticker | MMED (ticker) | MMED_f53c1ad9 | 2026-09-01 | earnings_transcript | ||||||||||||||
| Transition to direct commercial operations in additional key European markets, following the playbook from initial transitions. | in the fourth quarter | 2026-10-01 | 2026-12-31 | Expected to improve price and margins (ASP premiums at least 30% higher) and deepen relationships, but also involves an anticipated $15 million headwind from distributor destocking and inventory buybacks for 2026. | Ticker | TNDM (ticker) | TNDM_709c0ea7 | 2026-02-20 | earnings_transcript | ||||||||||||||
| European commercial launch of MiniMed Flex. | November of this year | 2026-11-01 | 2026-11-30 | This launch follows CE Mark approval and is expected to drive strong growth in international markets by expanding reach into new patients and increasing competitive conversions. | Ticker | MMED (ticker) | MMED_99ed2845 | 2026-09-01 | earnings_transcript | ||||||||||||||
| Regulatory filing for Insulet's fully closed-loop system for Type 2 diabetes. | supporting a regulatory filing in 2027 | 2027-01-01 | 2027-12-31 | Successful regulatory filing is a prerequisite for commercial launch, enabling Insulet to access the vast and underpenetrated Type 2 diabetes market with a highly differentiated product, impacting future revenue and valuation. | Ticker | PODD (ticker) | PODD_5dda514d | 2026-02-18 | earnings_transcript | ||||||||||||||
| Commercial launch of Insulet's next-generation Omnipod 6 system. | accelerate our innovation cycle as we prepare for launch in 2027 | 2027-01-01 | 2027-12-31 | This next-gen platform is designed to offer improved connectivity, flexibility, and personalized automation, crucial for maintaining competitive leadership and driving future revenue growth and investor sentiment. | Ticker | PODD (ticker) | PODD_93a0b76a | 2026-02-18 | earnings_transcript | ||||||||||||||
| Full U.S. launch of MiniMed Fit, a patch pump. | by summer next year | 2027-06-01 | 2027-08-31 | Fit brings MiniMed's differentiated therapy platform to the fastest-growing segment of the insulin pump market, expanding reach into new patients and driving competitive conversions. | Ticker | MMED (ticker) | MMED_21687391 | 2026-09-01 | earnings_transcript | ||||||||||||||
| Commercial launch of Insulet's fully closed-loop system for people with Type 2 diabetes. | a commercial launch in 2028 | 2028-01-01 | 2028-12-31 | This system is designed to make AID accessible to virtually everyone with Type 2 diabetes, significantly expanding the addressable market and driving future growth, potentially solidifying Insulet's leadership in this segment. | Ticker | PODD (ticker) | PODD_fdc63d7d | 2026-02-18 | earnings_transcript | ||||||||||||||
| Insulet's new manufacturing facility in Costa Rica becomes operational. | expected to be operational in 2029 | 2029-01-01 | 2029-12-31 | This investment in capacity and automation is critical for supporting long-term industry-leading growth and achieving continued margin expansion, impacting profitability and valuation. | Ticker | PODD (ticker) | PODD_55d4bc0d | 2026-02-18 | earnings_transcript |
Constituents
- AHCOT3— AdaptHealth Corp.
- FMST3— Fresenius Medical Care AG & Co. KGaA
- MMEDT3— MiniMed Group, Inc. Common Stock
- PODDT3— Insulet Corp.
- TNDMT3— Tandem Diabetes Care, Inc.
- ALURT3· no notes yet
- DVAT3· no notes yet
- FPH.NZT3· no notes yet
- INSPT3· no notes yet
- MDXGT3· no notes yet
- NYXHT3· no notes yet
- RMDT3· no notes yet
- SOM.AUT3· no notes yet
- VVOST3· no notes yet